Bavarian Nordic A/S said it has entered into a new supply contract with Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson valued at $13.9 million.
 
Bavarian Nordic will manufacture and deliver bulk drug substance of its MVA-BN Filo vaccine, which Janssen has licensed as part of its Ebola vaccine regimen.
 
Manufacturing of the vaccines will be initiated in 2020, supply will not occur until 2021.
 
“We are pleased to continue our strong collaboration with Janssen,” said Paul Chaplin, president and chief executive officer, Bavarian Nordic. “Ebola remains a significant threat to global health security, and the supply of vaccines for local citizens, healthcare workers and others who are being deployed in risk areas is crucial to prevent future outbreaks.”
 
The contract builds on Bavarian Nordic’s existing collaboration with Janssen, under which Bavarian Nordic has previously manufactured more than 2 million doses of MVA-BN Filo.
 
In May 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion, recommending approval of the Ebola vaccine regimen which consists of two components, Ad26.ZEBOV, which is given first, and MVA-BN Filo which is administered approximately eight weeks later as a second vaccination. The final approval is pending decision by the European Commission.